[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334721-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334721-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","tumor-growth-arrest-effect-of-tetrahydroquinazoline-derivative-human-topoisomerase-ii-alpha-inhibitor-in-hpv-negative-head-and-neck-squamous-cell-carcinoma","Tumor growth-arrest effect of tetrahydroquinazoline-derivative human topoisomerase II-alpha inhibitor in HPV-negative head and neck squamous cell carcinoma","","Oral malignancies remain highly morbid, with under 50% long-term survival despite therapeutic advances, creating a continued need for more effective treatment strategies. Human topoisomerase II is a validated chemotherapeutic target because it governs DNA replication, transcription, recombination, and chromosome segregation. This work reports ARN21934, a tetrahydroquinazoline derivative that preferentially inhibits the alpha isoform of topoII, and evaluates its antitumor efficacy across 2D cell cultures, 3D in vitro systems, and chick chorioallantoic membrane cancer models. The results support further preclinical development of ARN21934 and related topoII alpha inhibitors for oral neoplasms.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/tumor-growth-arrest-effect-of-tetrahydroquinazoline-derivative-human-topoisomerase-ii-alpha-inhibitor-in-hpv-negative-head-and-neck-squamous-cell-carcinoma/334721/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/tumor-growth-arrest-effect-of-tetrahydroquinazoline-derivative-human-topoisomerase-ii-alpha-inhibitor-in-hpv-negative-head-and-neck-squamous-cell-carcinoma/334721.png","ImageObject",300,407,{"name":42,"@type":43},"Ava Thompson","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are new treatments needed for HPV-negative head and neck squamous cell carcinoma?","Question",{"text":63,"@type":64},"HPV-negative HNSCCs are more aggressive and patients may not respond or may relapse after standard gold-standard therapy. Up to 40% of patients require modifications such as dose reduction, delays, or omissions due to toxicity and treatment challenges.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What role does human topoisomerase II play in cancer cells?",{"text":68,"@type":64},"Topoisomerase II regulates critical processes including DNA replication, transcription, recombination, and chromosome segregation. Its activity is linked to replication and cell-cycle phases and is associated with prognosis when its alpha isoform is highly expressed.",{"name":70,"@type":61,"acceptedAnswer":71},"What is ARN21934 and how does it work?",{"text":72,"@type":64},"ARN21934 is a tetrahydroquinazoline derivative designed to preferentially inhibit the alpha isoform of human topoisomerase II. It blocks topoII function without intercalating DNA and avoids accumulation of the covalent enzyme/DNA cleavage complex typical of topoII poisons.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334721,1790438043,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":4},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nTumor growth‑arrest effect oftetrahydroquinazoline‑derivative human topoisomerase II‑alpha inhibitor in HPV‑negative head and neck squamous cell carcinoma  \nPatrizia Sarogni1,2, Nicoletta Brindani2, Agata Zamborlin1,3,4, Alessandra Gonnelli1,5, Michele Menicagli6, Ana Katrina Mapanao7, Federico Munafò2, Marco DeVivo2* & Valerio Voliani1,8*  \nOral malignancies continue to have severe morbidity with less than 50% long‑term survival despite the advancement in the available therapies. There is a persisting demand for new approaches to establish more efficient strategies for their treatment. In this regard, the human topoisomerase II (topoII) enzyme is a validated chemotherapeutics target, as topoII regulates vital cellular processes such as DNA replication, transcription, recombination, and chromosome segregation in cells. TopoII inhibitors are currently used to treat some neoplasms such as breast and small cells lung carcinomas. Additionally, topoII inhibitors are under investigation for the treatment of other cancer types, including oral cancer. Here, we report the therapeutic effect of a tetrahydroquinazoline derivative (named ARN21934) that preferentially inhibits the alpha isoform of human topoII. The treatment efficacy of ARN21934 has been evaluated in 2D cell cultures, 3D in vitro systems, and in chick chorioallantoic membrane cancer models. Overall, this work paves the way for further preclinical developments of ARN21934 and possibly other topoII alpha inhibitors of this promising chemical class as a new chemotherapeutic approach for the treatment of oral neoplasms.  \nKeywords Topoisomerase, Head and neck, Alternative models, Tetrahydroquinazoline  \nHead and neck squamous cell carcinomas (HNSCCs) represent a wide class of epithelial neoplasms localized in the oral and nasal cavities, paranasal sinuses, salivary glands, pharynx, and larynx1,2. Generally, the strategies for the management of HNSCCs are different between locally advanced and early stage tumors3. Indeed, according with the most recent Clinical Practice Guidelines in Oncology (e.g. NCCN), the standard treatments in the early stage of the disease relies on conservative surgery or radiotherapy. Standard options for locally advanced HNSCCs are either surgery plus adjuvant chemo/radiotherapy or primary chemoradiotherapy alone, even if the best treatment regime is selected on a case-by-case analysis4,5. In this regard, the drugs of choice for the chemotherapy of HNSCCs are cisplatin-derivatives, even if their sub-optimal efficacy is limited due to the associated severe systemic toxicities (nephrotoxicity, neurotoxicity, ototoxicity, and emesis)6. In general, HPV-negative HNSCCs are more aggressive than HPV-positive HNSCC, and locally advanced patients may not respond or even relapse after receiving the gold standard therapy7. Indeed, these malignancies are challenging to treat, and up to 40% of patients require modifications ofthe treatment regimen (i.e., dose reduction, delays, and omissions)8. Therefore,  \n1Center for Nanotechnology Innovation@ NEST, Istituto Italiano di Tecnologia, Piazza San Silvestro, 12, 56126 Pisa, Italy. 2Molecular Modeling and Drug Discovery Lab, Istituto Italiano di Tecnologia, via Morego, 30, 16163 Genoa, Italy. 3NEST – Scuola Normale Superiore, Piazza San Silvestro, 12, 56126 Pisa, Italy. 4Present address: Ghent Research Group on Nanomedicines, Department of Pharmaceutics, Ghent University, Ottergemsesteenweg 460, B-9000 Ghent, Belgium. 5Department of Translational Medicine, University of Pisa, 56126 Pisa, Italy. 6Fondazione Pisana per la Scienza ONLUS, via Ferruccio Giovannini, 13, 56017 S. Giuliano Terme, Italy. 7Center for Radiopharmaceutical Sciences, Paul Scherrer Institute (PSI), 5232 Villigen, Switzerland. 8Department of Pharmacy, School of Medical and Pharmaceutical Sciences, University of Genoa, Viale Cembrano 4, 16148 Genoa, Italy.* email: marco.dev","cbCaisVkpXE17BN0","https://ap.wps.com/l/cbCaisVkpXE17BN0","pdf",6166488,"English","# Background\n## Clinical need in HPV-negative HNSCC\n## Topoisomerase II as a therapeutic target\n# Study rationale\n## Limitations of current chemotherapies\n## Tetrahydroquinazoline derivative strategy\n# Experimental evaluation overview\n## Efficacy in 2D, 3D, and in vivo-like models","[{\"question\":\"Why are new treatments needed for HPV-negative head and neck squamous cell carcinoma?\",\"answer\":\"HPV-negative HNSCCs are more aggressive and patients may not respond or may relapse after standard gold-standard therapy. Up to 40% of patients require modifications such as dose reduction, delays, or omissions due to toxicity and treatment challenges.\"},{\"question\":\"What role does human topoisomerase II play in cancer cells?\",\"answer\":\"Topoisomerase II regulates critical processes including DNA replication, transcription, recombination, and chromosome segregation. Its activity is linked to replication and cell-cycle phases and is associated with prognosis when its alpha isoform is highly expressed.\"},{\"question\":\"What is ARN21934 and how does it work?\",\"answer\":\"ARN21934 is a tetrahydroquinazoline derivative designed to preferentially inhibit the alpha isoform of human topoisomerase II. It blocks topoII function without intercalating DNA and avoids accumulation of the covalent enzyme/DNA cleavage complex typical of topoII poisons.\"}]","Tumor growth-arrest effect of tetrahydroquinazoline-derivative human topoisomerase II-alpha inhibitor in HPV-negative head and neck squamous cell carcinoma | PDF",1790008028,25]